TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

PF-07321332 Supply Agreement for Pandemic Purposes

Pharmaceutical products
UK
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Department of Health and Social Care: "PF-07321332 Supply Agreement for Pandemic Purposes". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityDepartment of Health and Social CareScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: Department of Health and Social Care
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for Department of Health and Social Care. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
11.8Bids / Report
54.4% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 451 active published awards; 397 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityDepartment of Health and Social Care
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published17 Nov 2021, 18:41 GMT
Last source update17 Nov 2021, 18:41 GMT
Recurring procurementNot published
ClassificationPharmaceutical products
Delivery area
UK
OCIDocds-h6vhtk-02f7bb
What is being bought
Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative. So far there are no primary care antiviral drugs that can be easily dispensed specifically to treat SARS-CoV-2 and prevent its transmission in the community.This agreement is for the procurement of 250,000 units of PF-07321332/ritonavir . It is one of the first oral and direct-acting antiviral drugs globally and is part of the UK’s multi-layered approach to COVID-19.
What changed
From the official release history
  1. Status changed to complete
    17 Nov 2021, 18:41 GMT
  2. Official notice release published
    17 Nov 2021, 18:41 GMT
  3. Buyer information updated
    17 Nov 2021, 18:41 GMT
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    cancelled
    Published valueNot published
    Procurement of PF-07321332/ritonavir.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    17 Nov 2021, 18:41 GMT
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 18 Oct 2021, 00:00 BST · Not published
Commercial outcome and competition
Awards
Pfizer Limited
Not published · Not published · active
Contracts
Contract
Not published · signed 18 Oct 2021, 00:00 BST · active
Bid statistics
bids: 1 (lot 1)
electronicBids: 0 (lot 1)
foreignBidsFromEU: 0 (lot 1)
foreignBidsFromNonEU: 0 (lot 1)
highestValidBidValue: 1 (lot 1)
lowestValidBidValue: 1 (lot 1)
smeBids: 0 (lot 1)
Buyer and organisations in this procedure

Department of Health and Social Care

Contracting authority GB-FTS-43
View buyer profile
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleRegulation 32(2)(c)The procurement was initiated on the basis that Regulation 32(2)(c) was applicable. In April 2021, the Antivirals Task Force (ATF) was established as it was recognised there was an urgent to find alternative novel anti-viral treatments. As far as is strictly necessary: The use of antivirals was identified as strictly necessary for the cohort of individuals for whom a vaccine is not an option. There are genuine reasons for extreme urgency: The procurement of antivirals aims to protect vulnerable cohorts of the population. This risk of public health presents a genuine emergency.The events that have led to the need for extreme urgency were unforeseeable: There are many aspects of the COVID-19 pandemic, which have been entirely unforeseeable. DHSC is acting on the newest information it has available to tailor its COVID-19 response accordingly. The situation is not attributable to the contracting authority: The situation of extreme urgency is not attributable to DHSC.It is impossible to comply with the usual timescales in the PCR: When the need for antivirals was urgently identified in April 2021, DHSC conducted a comprehensive market review. The result of this exercise was that it became clear that a procurement exercise could not be run due to the absence of competition. If the ATF were to run a procurement process now, it would worsen DHSC’s position.Regulation 32 (2) (b) (ii)In the course of this procurement, it has become clear to DHSC that Regulation 32(2)(b)(ii) is applicable. The antivirals market is inverted, with an imbalance between demand and supply and limited worldwide supply capacity. This means there will be a finite supply of antivirals available in 2021/22: to date only two antivirals have received or have the potential to gain MHRA approval for Autumn/Winter 2021.Looking forward, DHSC is expected to publish a Prior Information Notice (PIN) in November in respect of its likely further portfolio requirements with a view to running future open procurement exercises where possible. Please see Contracts Finder Notice for full justification.